Glenmede Trust’s Nektar Therapeutics NKTR Stock Holding History

Glenmede Trust’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$998K	Buy	13,865 +5,275	+61%	+$300K	﹤0.01%	740
2025 Q4	$363K	Buy	+8,590	New	+$481K	﹤0.01%	1060
2020 Q4	–	Sell	-94	Closed	-$23K	–	1872
2020 Q3	$23K	Sell	94 -4	-4%	-$1.26K	﹤0.01%	1575
2020 Q2	$34K	Sell	98 -78	-44%	-$24.3K	﹤0.01%	1415
2020 Q1	$56K	Hold	176	–	–	﹤0.01%	1640
2019 Q4	$56K	Hold	176	–	–	﹤0.01%	1640
2019 Q3	$47	Hold	176	–	–	﹤0.01%	1683
2019 Q2	$93	Hold	176	–	–	﹤0.01%	1433
2019 Q1	$88	Hold	176	–	–	﹤0.01%	1453
2018 Q4	$86	Buy	+176	New	+$106K	﹤0.01%	1407
2018 Q3	–	Sell	-33	Closed	-$24K	–	1686
2018 Q2	$24K	Buy	33 +3	+10%	+$3.46K	﹤0.01%	1664
2018 Q1	$26K	Hold	30	–	–	﹤0.01%	1859
2017 Q4	$26K	Buy	+30	New	+$17.7K	﹤0.01%	1859
2016 Q4	–	Sell	-4	Closed	-$1K	–	2562
2016 Q3	$1K	Buy	+4	New	+$1.03K	﹤0.01%	2487
2015 Q4	–	Sell	-145	Closed	-$23K	–	2728
2015 Q3	$23K	Hold	145	–	–	﹤0.01%	1855
2015 Q2	$27K	Hold	145	–	–	﹤0.01%	1810
2015 Q1	$23K	Hold	145	–	–	﹤0.01%	1902
2014 Q4	$33K	Buy	+145	New	+$31K	﹤0.01%	1876

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Glenmede Trust's NKTR Position: Q1 2026 in Review

Glenmede Trust increased its Nektar Therapeutics (NKTR) stake by 61% in Q1 2026, buying an estimated $300K and bringing the position to 13,865 shares worth $998K. The position accounts for ﹤0.01% of the portfolio, ranked #740.

Glenmede Trust first reported a position in NKTR in Q4 2014 and has held it in 18 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Glenmede Trust held 13,865 shares of Nektar Therapeutics worth $998K as of Q1 2026.
Glenmede Trust bought 5,275 Nektar Therapeutics shares in Q1 2026, an estimated $300K.
Nektar Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #740 holding.
Glenmede Trust first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 18 quarters since.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.